A case of psoriasis complicated by breast cancer after systemic treatments including biologics

Shin Morizane, Saeko Sugimoto, Takayuki Motoki, Norihisa Katayama, Masako Omori, Keiji Iwatsuki

Research output: Contribution to journalArticle

Abstract

Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.

LanguageEnglish
Pages185-187
Number of pages3
JournalActa Medica Okayama
Volume72
Issue number2
Publication statusPublished - Jan 1 2018

Fingerprint

Biological Products
Psoriasis
Etretinate
Breast Neoplasms
Methotrexate
Cyclosporine
Skin
Psoriatic Arthritis
Therapeutics
Neoplasms
Ustekinumab
Adalimumab

Keywords

  • Biologics
  • Malignancy
  • Psoriasis
  • Systemic therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

A case of psoriasis complicated by breast cancer after systemic treatments including biologics. / Morizane, Shin; Sugimoto, Saeko; Motoki, Takayuki; Katayama, Norihisa; Omori, Masako; Iwatsuki, Keiji.

In: Acta Medica Okayama, Vol. 72, No. 2, 01.01.2018, p. 185-187.

Research output: Contribution to journalArticle

Morizane, Shin ; Sugimoto, Saeko ; Motoki, Takayuki ; Katayama, Norihisa ; Omori, Masako ; Iwatsuki, Keiji. / A case of psoriasis complicated by breast cancer after systemic treatments including biologics. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 2. pp. 185-187.
@article{fee3a50ccaaa45cbb36bade6d6da03d4,
title = "A case of psoriasis complicated by breast cancer after systemic treatments including biologics",
abstract = "Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.",
keywords = "Biologics, Malignancy, Psoriasis, Systemic therapy",
author = "Shin Morizane and Saeko Sugimoto and Takayuki Motoki and Norihisa Katayama and Masako Omori and Keiji Iwatsuki",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "185--187",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - A case of psoriasis complicated by breast cancer after systemic treatments including biologics

AU - Morizane, Shin

AU - Sugimoto, Saeko

AU - Motoki, Takayuki

AU - Katayama, Norihisa

AU - Omori, Masako

AU - Iwatsuki, Keiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.

AB - Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab.

KW - Biologics

KW - Malignancy

KW - Psoriasis

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85047186433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047186433&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 185

EP - 187

JO - Acta Medica Okayama

T2 - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -